According to InvestingPro analysis, Novartis currently ... investor confidence in the coming years. Pipeline development is inherently risky in the pharmaceutical industry, and Novartis is not ...

While the pandemic has been the focus of R&D attention for much of 2020, that is slowly beginning to shift towards other projects in the big pharma pipeline. pharmaphorum’s news editor ...

Novartis has streamlined its operations to concentrate solely on its Pharmaceutical (TADAWUL ... emphasize the importance of the company's current late-stage pipeline in meeting consensus expectations ...

Novartis has streamlined its operations to concentrate solely on its Pharmaceutical ... analysis, InvestingPro offers detailed research reports covering Novartis's pipeline potential and financial ...